Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: July 28, 2023
Lymphoepithelial
malignancy
is
an
extremely
rare
carcinoma
of
the
breast
characterized
by
a
confusing
histopathological
picture
resembling
medullary
carcinomas,
lymphoma,
etc.
It
has
also
been
reported
in
other
regions
body
like
salivary
glands,
nasopharyngeal
area
and
sometimes
lung.
Due
to
its
presence
difficult
diagnosis,
treatment
often
prolonged
delayed.
Here
we
present
case
report
56-year-old
lady
who
was
eventually
diagnosed
as
lymphoepithelial
breast.
Her
journey
evaluation
fraught
with
pathological
nuances
elimination
drill
multiple
differentials
before
concluding
this
diagnosis.
Although
lymphoepithelial-like
entity,
cases
have
literature
their
review
mandated
further
our
clinical
knowledge
about
oncological
expected
prognosis
such
future.
Our
patient
underwent
simple
mastectomy,
followed
chemotherapy,
radiotherapy,
completely
asymptomatic
now.
She
cancer-free
for
last
seven
years
so
far.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: May 7, 2024
Abstract
Breast
cancer,
the
most
frequent
female
malignancy,
is
often
curable
when
detected
at
an
early
stage.
The
treatment
of
metastatic
breast
cancer
more
challenging
and
may
be
unresponsive
to
conventional
therapy.
Immunotherapy
crucial
for
treating
but
its
resistance
a
major
limitation.
tumor
microenvironment
(TME)
vital
in
modulating
immunotherapy
response.
Various
microenvironmental
components,
such
as
cancer-associated
fibroblasts
(CAFs),
tumor-associated
macrophages
(TAMs),
myeloid-derived
suppressor
cells
(MDSCs),
are
involved
TME
modulation
cause
resistance.
This
review
highlights
role
stromal
microenvironment,
including
involvement
CAF-TAM
interaction,
alteration
metabolism
leading
failure,
other
latest
strategies,
high
throughput
genomic
screening,
single-cell
spatial
omics
techniques
identifying
immune
genes
regulating
emphasizes
therapeutic
approach
overcome
through
CAF
reprogramming,
TAM
polarization,
metabolism,
alterations.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(13), P. 6815 - 6815
Published: June 21, 2024
Copy
number
alterations
(CNAs),
resulting
from
the
gain
or
loss
of
genetic
material
as
little
50
base
pairs
big
entire
chromosome(s),
have
been
associated
with
many
congenital
diseases,
de
novo
syndromes
and
cancer.
It
is
established
that
CNAs
disturb
dosage
genomic
regions
including
enhancers/promoters,
long
non-coding
RNA
gene(s)
among
others,
ultimately
leading
to
an
altered
balance
key
cellular
functions.
In
cancer,
almost
all
steps
disease:
predisposition,
initiation,
development,
maintenance,
response
treatment,
resistance,
relapse.
Therefore,
understanding
how
specific
contribute
tumourigenesis
may
provide
prognostic
insight
lead
development
new
therapeutic
approaches
improve
patient
outcomes.
this
review,
we
a
snapshot
what
currently
known
about
incorporating
topics
regarding
their
detection,
clinical
impact,
origin,
nature,
discuss
integration
innovative
engineering
strategies,
highlight
potential
for
targeting
using
novel,
dosage-sensitive
less
toxic
therapies
CNA-driven
Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 9, 2025
Antibody-recruiting
molecules
(ARMs)
are
bivalent
that
contain
a
cell-binding
domain
and
an
antibody-binding
domain.
ARMs
designed
to
redirect
circulating
endogenous
antibodies
from
the
bloodstream
surface
of
cancer
cells
thereby
trigger
innate
immune-mediated
killing
latter.
The
current
generation
clinically
explored
relies
on
synthetic
small
molecule
haptens.
However,
their
effectiveness
is
restricted
by
low
affinity
available
repertoire
anti-hapten
antibodies.
Utilizing
high-affinity
allergen-specific
could
potentially
circumvent
this
issue.
In
study,
genetically
encoded
antibody-recruiting
strategy
utilizes
lipid
nanoparticles
(LNPs)
deliver
mRNA
encoding
house
dust
mite
allergen
Der
p
2,
fused
cell
membrane
anchor,
induce
display
enable
recruitment
anti-Der
2
antibodies,
presented.
LNP-treated
cause
greatly
reduced
pulmonary
tumor
burden
in
immunized
mice,
compared
untreated
or
nonimmunized
mice.
Reduced
growth
dependent
neutrophils
identified
as
key
immune
subset
recognizing
eliminating
2-displaying
cells.
These
findings
emphasize
LNPs
powerful
tool
for
generating
ARM
strategy,
with
potential
applications
immunotherapy.
Journal of drug targeting,
Journal Year:
2023,
Volume and Issue:
32(1), P. 45 - 56
Published: Dec. 14, 2023
Monoclonal
antibodies
(mAbs)
are
integral
to
cancer
treatment
over
conventional
non-specific
therapy
methods.
This
study
provides
a
scoping
review
of
the
clinically
approved
mAbs,
focusing
on
current
application
different
nanocarrier
technologies
as
drug
delivery
targets
for
mAb-conjugated
nanoparticles
(NPs)
potential
features
breast
(BC)
treatment.
An
extensive
literature
search
was
conducted
between
years
2000
and
2023
using
various
sources
databases.
The
first
part
covered
mAb
classification,
types,
mechanisms
action,
pharmacokinetics
clinical
applications
in
BC.
second
polymeric,
lipid
inorganic-based
NPs,
which
variety
NPs
targeting
A
total
20
relevant
studies
were
enrolled
indicating
there
three
types
nanoparticular
systems
(polymeric
inorganic
lipid-based
NPs)
that
can
be
used
BC
by
being
loaded
with
active
substances
conjugated
these
antibodies.
While
mAbs
have
altered
way
due
cells
specifically,
nanoparticulate
is
important
BC,
still
investigated
distinctive
promising
methods
employed
effective
Asian Journal of Advances in Research,
Journal Year:
2024,
Volume and Issue:
7(1), P. 159 - 173
Published: April 24, 2024
A
new
era
in
cancer
treatment
has
begun
with
the
development
of
monoclonal
antibodies
(mAbs),
which
have
improved
therapeutic
results
and
precision
targeting
to
a
great
extent.
Specialized
(mAbs)
are
engineered
attach
specifically
antigens,
allowing
them
directly
target
tumor
cells
influence
immune
system
for
purposes.
Significant
advancements
this
field
include
approval
clinical
efficacy
mAbs
that
B-cell
lymphomas
HER2-positive
breast
cancer.
Notable
cases
like
as
trastuzumab
rituximab
highlight
real
benefits
these
treatments,
better
patient
outcomes
survival
rates.
Furthermore,
by
triggering
body's
immunological
defenses
against
cells,
checkpoint
inhibitors
pembrolizumab
completely
changed
way
is
treated.
For
individuals
previously
difficult-to-treat
illnesses,
innovative
technique
shown
extraordinary
success
across
variety
types.
Innovative
approaches
including
antibody-drug
conjugates
bispecific
also
been
produced
ongoing
developments
mAb
engineering.
These
technical
miracles
improve
overall
safety
profile
(mAb)
therapeutics
compensating
off-target
effects
optimizing
efficacy.
There
still
issues,
such
toxicity
emergence
drug
resistance,
spite
significant
progress.
Even
Nevertheless,
continued
research
initiatives
enormous
potential
customized
plans.
advances
promise
future
patients
everywhere
highlighting
quick
evolution
therapies
encouraging
increased
innovation
vital
area
medicine.
